El Sobrante, CA, United States of America

Cynthia Shafer

USPTO Granted Patents = 30 (Patent Applications = 2)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 5 (Patent Applications = 1)

Average Co-Inventor Count = 8.0

ph-index = 12

Forward Citations = 495(Granted Patents)

Location History:

Emeryville, CA (US) (2009 - 2010)
Moraga, CA (US) (2006 - 2014)
El Sobrante, CA (US) (2003 - 2018)

Company Filing History:

Novartis Vaccines & Diagnostics, Gmbh

patents

Years Active: 2003-2018

Loading Chart...

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10112931 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2018-10-30),

2. 9688672 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2017-06-27),

3. 9546173 - Substituted pyrrolo[3,4-d]pyrimidines as kinase inhibitors (2017-01-17),

4. 9434719 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2016-09-06),

5. 8957068 - 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH (2015-02-17),

6. 8865732 - Heterocyclic compounds and uses thereof (2014-10-21),

7. 8822497 - PIM kinase inhibitors and methods of their use (2014-09-02),

8. 8614330 - Substituted benz-azoles and methods of their use as inhibitors of RAF kinase (2013-12-24),

9. 8592459 - Substituted benzimidazoles and methods of their use (2013-11-26),

10. 8415382 - Substituted benzazoles and methods of their use as inhibitors of RAF Kinase (2013-04-09),

11. 8129394 - Heteroaryl-substituted imidazole compounds and uses thereof (2012-03-06),

12. 7732465 - Substituted benzimidazoles and methods of their use (2010-06-08),

13. 7728010 - Substituted benz-azoles and methods of their use as inhibitors of Raf kinase (2010-06-01),

14. 7671059 - 2-amino-7,8-dihydro-6H-pyrido[4,3-d]pyrimidin-5-ones (2010-03-02),

15. 7642278 - Indazole benzimidazole compounds (2010-01-05),

Title: Innovations and Contributions of Cynthia Shafer in Pharmaceutical Patents

Introduction

Cynthia Shafer, based in El Sobrante, CA, has established herself as a prominent inventor in the pharmaceutical field with an impressive portfolio of 30 patents. Her work primarily revolves around innovative compounds that have significant implications for treating various diseases.

Latest Patents

Among her latest contributions are patents related to "3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant IDH". This invention focuses on a novel formula that includes a compound designed to inhibit mutant IDH proteins exhibiting neomorphic activity. The compounds in these patents are intended for use in treating cell-proliferation disorders, particularly cancer, showcasing Cynthia’s commitment to addressing critical health challenges.

Career Highlights

Throughout her career, Cynthia has worked with notable companies such as Novartis AG and Chiron Corporation. Her time at these organizations has undoubtedly influenced her innovative approach to pharmaceutical development and her ability to navigate the complexities of patenting new inventions.

Collaborations

Cynthia has collaborated with esteemed colleagues, including Paul A. Renhowe and Christopher McBride, which highlights her capacity to work within teams comprised of talented individuals in the field of pharmaceutical research and development.

Conclusion

Cynthia Shafer's impactful contributions to the field of pharmaceuticals through her patents and collaborations with leading companies and individuals mark her as a significant figure in the innovation landscape. Her focus on treatments for complex diseases like cancer demonstrates her dedication to advancing health solutions through inventive approaches.

This text is generated by artificial intelligence and may not be accurate.